Last updated: 2026-09-16 10:31:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Immucell Corp. (ICCC) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $9.66, with a market capitalisation of $88.19M and a P/E ratio of 110.50. Over the past 52 weeks, its price has ranged from $4.52 to $12.10. This page covers its latest market performance, valuation, price trends and company information.
$88.19M | |
$9.75 | |
$25.55 | |
$1.33 | |
$9.71 | |
20.77K | |
28.58K | |
110.50 | |
$12.10 | |
$4.52 | |
-- | |
-- |
Immucell Corp. (ICCC) is trading at $9.72 in pre-market trading as of 2026-09-15 23:31:00, up 0.05% ($0.00) from the previous close of $9.71
Pre-market trading shows how investors are pricing ICCC before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Immucell Corp. (ICCC) moved from $9.90 to $9.66, representing a decline of 2.39% ($0.24).
The stock traded between $9.40 and $10.02 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 12.97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 67.8%
ICCC is currently trading at $9.66, placing it 67.8% of the way from its 52-week low of $4.52 to its 52-week high of $12.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immucell Corp. (ICCC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.